254 related articles for article (PubMed ID: 11173815)
41. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
42. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Saleh S; Ain-Shoka AA; El-Demerdash E; Khalef MM
Chemotherapy; 2009; 55(6):399-406. PubMed ID: 19955745
[TBL] [Abstract][Full Text] [Related]
43. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
44. [Cis-diamminedichloroplatinum penetration into the cerebrospinal fluid of the lateral ventricle, postoperative cavity, and lumbar subarachnoid space with or without pre-intravenous mannitol administration in patients with brain metastasis from lung cancer].
Nakagawa H; Yamada M; Tamura M; Yoshida M; Shindo M; Nishiyama H; Sakai S
Gan To Kagaku Ryoho; 2014 Mar; 41(3):317-24. PubMed ID: 24743276
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
DeWoskin RS; Riviere JE
Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
[TBL] [Abstract][Full Text] [Related]
46. Renal metallothionein and platinum levels in diabetic and nondiabetic rats injected with cisplatin.
Cacini W; Singh Y
Proc Soc Exp Biol Med; 1991 Jul; 197(3):285-9. PubMed ID: 2068122
[TBL] [Abstract][Full Text] [Related]
47. [Experimental studies of the protective effect of deferoxamine mesilate on cisplatin induced toxicity].
Watanabe H; Kanno H
Nihon Jibiinkoka Gakkai Kaiho; 1998 Aug; 101(8):967-78. PubMed ID: 9778942
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats.
Zhou H; Fujigaki Y; Kato A; Miyaji T; Yasuda H; Tsuji T; Yamamoto T; Yonemura K; Hishida A
Am J Physiol Renal Physiol; 2006 Jul; 291(1):F225-35. PubMed ID: 16467127
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
51. Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats.
González R; Romay C; Borrego A; Hernández F; Merino N; Zamora Z; Rojas E
Mediators Inflamm; 2005 Aug; 2005(3):139-43. PubMed ID: 16106099
[TBL] [Abstract][Full Text] [Related]
52. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
53. Effect of diabetes on biodistribution, nephrotoxicity and antitumor activity of cisplatin in mice.
da Silva Faria MC; Santos NA; Carvalho Rodrigues MA; Rodrigues JL; Barbosa Junior F; Santos AC
Chem Biol Interact; 2015 Mar; 229():119-31. PubMed ID: 25665769
[TBL] [Abstract][Full Text] [Related]
54. The role of metallothionein in the reduction of cisplatin-induced nephrotoxicity by Bi3(+)-pretreatment in the rat in vivo and in vitro. Are antioxidant properties of metallothionein more relevant than platinum binding?
Boogaard PJ; Slikkerveer A; Nagelkerke JF; Mulder GJ
Biochem Pharmacol; 1991 Feb; 41(3):369-75. PubMed ID: 1994896
[TBL] [Abstract][Full Text] [Related]
55. [Studies on pharmacokinetics of platinum after internal iliac artery infusion of cisplatin in rabbits].
Kanamori Y
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Jan; 45(1):31-7. PubMed ID: 8436840
[TBL] [Abstract][Full Text] [Related]
56. Effect of L-histidinol on cisplatin nephrotoxicity in the rat.
Badary OA; Nagi MN; Al-Sawaf HA; Al-Harbi M; Al-Bekairi AM
Nephron; 1997; 77(4):435-9. PubMed ID: 9434066
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
58. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.
Serpeloni JM; Batista BL; Angeli JP; Barcelos GR; Bianchi Mde L; Barbosa F; Antunes LM
J Toxicol Environ Health A; 2013; 76(6):345-53. PubMed ID: 23557233
[TBL] [Abstract][Full Text] [Related]
59. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
60. Studies on nephrotoxicity following a single and repeated administration of cis-diamminedichloroplatinum (CDDP) in rats.
Mizushima Y; Nagahama H; Yokoyama A; Morikage T; Yano S
Tohoku J Exp Med; 1987 Feb; 151(2):129-35. PubMed ID: 3576612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
